ArticlePloS one2026
Analysis of the genotyping of circulating strains and characteristics of Glycoprotein E of Varicella-Zoster Virus in Shanxi Province, China.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVaricella-zoster virus (VZV), a neurotropic and epidermotropic herpesvirus, causes varicella (chickenpox) upon primary infection and reactivates later in life to cause herpes zoster (HZ), which is associated with significant morbidity, particularly postherpetic neuralgia (PHN). VZV genotyping and characterization of key viral proteins, such as glycoprotein E (gE), are critical for understanding viral circulation, distinguishing vaccine from wild-type strains, and optimizing vaccine strategies. In China, clade 2 is the predominant VZV genotype, but data from Shanxi Province remain limited.
methodsForty herpes fluid specimens from clinically diagnosed herpes zoster (HZ) patients in Shanxi Province were collected. Quantitative polymerase chain reaction (qPCR) was used to detect viral DNA for definitive diagnosis. Six single-nucleotide polymorphisms (SNPs) in the open reading frame (ORF) 22 and ORF 38 fragments of positive specimens were analyzed by PCR and Sanger sequencing to determine viral genotypes. Four SNPs in ORF 38 and ORF 62 were analyzed to distinguish between vaccine and wild-type strains. The full-length nucleotide sequences of the gE gene in VZV-positive clinical specimens were determined. Sequence analysis was performed using Sequencher 5.4.6 and MEGA 11.0.11 software, with comparative reference to VZV strains retrieved from GenBank, to analyze the genetic characteristics of the VZV gE in Shanxi Province. The potential impact of amino acid substitutions caused by nucleotide mutations on the function of the gE protein was predicted using PROVEAN. Mutations in the gE protein were visualized using AlphaFold2 and PyMOL 2.6.0.
resultsAll 40 specimens tested positive for VZV and were identified as wild-type clade 2 strains. Strain SX-17 exhibited a T → C mutation at position 107252. Notably, two strains (SX-01 and SX-04) lacked the 69424 SNP locus in ORF 38. gE gene sequencing revealed amino acid substitutions compared to the Dumas reference strain, including T40I (39 strains), H98P (SX-18), V489L (SX-04 and SX-05), and N529S (SX-08). PROVEAN analysis classified all mutations as neutral (scores > -2.5), with no impact on critical gE functional domains.
conclusionsThe dominant VZV genotype in Shanxi Province is wild-type clade 2. A T → C mutation at position 107252 exists in clade 2 strains. The mutation sites of gE identified so far have not exerted a significant impact on the VZV functions, suggesting that VZV vaccination can serve as a critical measure for herpes zoster prevention in Shanxi Province.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.